# A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)

> **NCT00481663** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 555 (actual)

## Conditions studied

- Type II Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Placebo to sitagliptin
- **DRUG:** Metformin
- **DRUG:** Rescue

## Key facts

- **NCT ID:** NCT00481663
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08-19
- **Primary completion:** 2004-07-21
- **Final completion:** 2006-05-14
- **Target enrollment:** 555 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481663, "A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00481663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*